Absci Corp

ABSI

Healthcare|Biotechnology|USA

$10.60

-0.87 (-7.59%)

Tangible Book

$0.85

About

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

Stock Price

+288.1%(1Y)

Pipeline Summary

1 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Recruiting: 1

Active Trials (1)

Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

NCT07317544Androgenetic Alopecia (AGA)

Phase 1Phase 2Recruiting

Enrollment: 227 participants

BioScore

4.3/10

Cautious

Ownership

Recent Insider Trades

Szela Mary TBUY

2026-06-3012,900 shares @ $11.54

Pangalos Menelas NBUY

2026-05-1337,453 shares @ $5.36

Busch AndreasBUY

2026-03-12100,000 shares @ $2.29

Pangalos Menelas NBUY

2026-02-2775,095 shares @ $2.74

McClain SeanSELL

2026-02-0226,761 shares @ $2.99

Recent News

2026-07-07 00:25:29

2026-07-06 13:00:08

2026-07-02 13:33:04

2026-06-25 12:33:55

Data last updated: Jul 13, 2026, 12:46 PM